Research
Energy balance
Individuals in the Persistent+GLP-1 naive cohort achieved a mean weight reduction of 12.9% at 6-months post-index.
Practitioners can expect significant weight loss in eligible patients using tirzepatide over a 6-month period.
StrongSupportsmedium confidence
Individuals in the Persistent+GLP-1 naive cohort with pre- and post-index weight and BMI measurements (n = 200) achieved mean weight reduction of 12.9 % at 6-months post-index.
Why this rating
Based on the retrospective observational study design with a substantial sample size.
Source
Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States
Emily R. Hankosky et al. · Diabetes & Metabolism · 2025
cohort · n=4177Cited 11×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →